These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37154966)

  • 1. Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study.
    Haddaji A; Ouladlahsen A; Lkhider M; Bensghir R; Jebbar S; Hilmi S; Abbadi I; Sodqi M; Marih L; Pineau P; El Filali KM; Ezzikouri S
    Arch Microbiol; 2023 May; 205(6):223. PubMed ID: 37154966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-α levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects.
    De Pablo-Bernal RS; Ruiz-Mateos E; Rosado I; Dominguez-Molina B; Alvarez-Ríos AI; Carrillo-Vico A; De La Rosa R; Delgado J; Muñoz-Fernández MA; Leal M; Ferrando-Martínez S
    J Antimicrob Chemother; 2014 Nov; 69(11):3041-6. PubMed ID: 25011654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
    Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
    BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
    Peterson TE; Landon C; Haberlen SA; Bhondoekhan F; Plankey MW; Palella FJ; Piggott DA; Margolick JB; Brown TT; Post WS; Wu KC
    BMC Cardiovasc Disord; 2022 Sep; 22(1):393. PubMed ID: 36057773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.
    Hattab S; Guiguet M; Carcelain G; Fourati S; Guihot A; Autran B; Caby F; Marcelin AG; Costagliola D; Katlama C
    HIV Med; 2015 Oct; 16(9):553-62. PubMed ID: 25944318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymptomatic HIV People Present Different Profiles of sCD14, sRAGE, DNA Damage, and Vitamins, according to the Use of cART and CD4
    Tasca KI; Correa CR; Caleffi JT; Mendes MB; Gatto M; Manfio VM; de Camargo CC; Tavares FC; Biasin M; de Souza LDR
    J Immunol Res; 2018; 2018():7531718. PubMed ID: 29992171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.
    Højen JF; Rasmussen TA; Andersen KL; Winckelmann AA; Laursen RR; Gunst JD; Møller HJ; Fujita M; Østergaard L; Søgaard OS; Dinarello CA; Tolstrup M
    Mol Med; 2015 Apr; 21(1):337-45. PubMed ID: 25879630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls.
    Knudsen AD; Bouazzi R; Afzal S; Gelpi M; Benfield T; Høgh J; Thomsen MT; Trøseid M; Nordestgaard BG; Nielsen SD
    BMC Infect Dis; 2022 May; 22(1):451. PubMed ID: 35546661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Integrase Strand Transfer Inhibitors (INSTIs) and Protease-Boosted Inhibitors (PIs) on the Reduction in Chronic Immune Activation in a Virally Suppressed, Mainly Male Population Living with HIV (PLWH).
    Nitsotolis T; Kyriakoulis KG; Kollias A; Papalexandrou A; Kalampoka H; Mastrogianni E; Basoulis D; Psichogiou M
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399618
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation.
    Monnig MA; Cohen R; Ramratnam B; McAdams M; Tashima K; Monti PM
    Alcohol Clin Exp Res; 2019 Jun; 43(6):1126-1134. PubMed ID: 30908642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
    Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.
    Wada NI; Jacobson LP; Margolick JB; Breen EC; Macatangay B; Penugonda S; Martínez-Maza O; Bream JH
    AIDS; 2015 Feb; 29(4):463-71. PubMed ID: 25630041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected inflammatory and coagulation biomarkers pre-viral suppression in people with human immunodeficiency virus (HIV) infection without overt cardiovascular disease: Is there a need to redefine reference indices?
    Louw S; Mayne ES; Jacobson BF; Mayne AL
    Cytokine; 2023 May; 165():156174. PubMed ID: 36996538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection.
    Dinh DM; Volpe GE; Duffalo C; Bhalchandra S; Tai AK; Kane AV; Wanke CA; Ward HD
    J Infect Dis; 2015 Jan; 211(1):19-27. PubMed ID: 25057045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence of a synergistic effect of HIV infection and diabetes mellitus type 2 on fat distribution, plasma adiponectin or inflammatory markers.
    Hove-Skovsgaard M; Abildgaard J; Gelpi M; Gaardbo JC; Kolte L; Ullum H; Trøseid M; Lindegaard B; Nielsen SD
    BMC Infect Dis; 2020 Nov; 20(1):882. PubMed ID: 33238950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Systemic Inflammation, Immune Activation, and Impaired Lung Function Among People Living With HIV in Rural Uganda.
    North CM; Muyanja D; Kakuhikire B; Tsai AC; Tracy RP; Hunt PW; Kwon DS; Christiani DC; Okello S; Siedner MJ
    J Acquir Immune Defic Syndr; 2018 Aug; 78(5):543-548. PubMed ID: 29683991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
    Quiros-Roldan E; Castelli F; Bonito A; Vezzoli M; Calza S; Biasiotto G; Zanella I;
    Cytokine; 2020 Feb; 126():154884. PubMed ID: 31670006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
    Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
    Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer.
    Taylor BS; So-Armah K; Tate JP; Marconi VC; Koethe JR; Bedimo RJ; Butt AA; Gibert CL; Goetz MB; Rodriguez-Barradas MC; Womack JA; Gerschenson M; Lo Re V; Rimland D; Yin MT; Leaf D; Tracy RP; Justice AC; Freiberg MS
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):500-508. PubMed ID: 28696344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.
    Van der Watt JJ; Wilkinson KA; Wilkinson RJ; Heckmann JM
    BMC Infect Dis; 2014 Feb; 14():71. PubMed ID: 24512313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.